Skip to main content
. 2021 May;27(5):1416–1426. doi: 10.3201/eid2705.203662

Table 1. Characteristics of patients identified in multicenter surveillance for Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae, Italy*.

Characteristics KPC-Kp patients, n = 1,071
Sex
M 694 (64.8)
F
377 (35.2)
Median age (IQR)
72 (61–80)
Ward of isolation
Intensive care unit 275 (25.7)
Infectious diseases 81 (7.6)
Surgery 149 (13.9)
Geriatrics 47 (4.4)
Oncology 34 (3.2)
Hematology 42 (3.9)
Other medical wards
443 (41.4)
KPC-Kp colonization in previous 12 mo 333 (31.1)
Hospitalization in previous 12 mo 865 (80.8)
Antimicrobial therapy in the 30 d before hospitalization 782 (73.0)
Major surgery in the previous 30 d
262 (24.4)
Underlying conditions† 989 (92.3)
Congestive heart failure 192 (17.9)
Peripheral vascular disease 197 (18.4)
Cerebrovascular disease 205 (19.1)
Chronic lung disease 202 (18.9)
Chronic renal failure 304 (28.4)
Cancer 244 (22.8)
Diabetes
163 (15.2)
Charlson index, median (IQR) 6 (4–8)
Central venous catheter at isolation 414 (38.7)
Urinary catheter at isolation 562 (52.5)
Immunosuppressive therapy 209 (19.5)
Days of hospitalization, median (IQR)
25 (14–45)
KPC-Kp acquisition characteristics‡
Severe infection 221 (20.6)
Mild infection 109 (10.2)
Colonizationsur
741 (69.2)
Median time from hospitalization to isolation of strain, d (IQR)‡
Severe infection 12 (2–22)
Mild infection 11 (2–25)
Colonizationsur
6 (1–17)
Median time from strain isolation to discharge or death, d (IQR)‡
Severe infection 18 (9–35)
Mild infection 20 (12–35)
Colonizationsur 13 (6–22)

*Values are no. (%) except as indicated. IQR, interquartile range; KPC-Kp, Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae.
†Underlying conditions and devices are listed when present in >10% of patients.
‡Severe infection included bloodstream or lower respiratory tract infection plus septic shock from other sites; Mild infection included infections from other sites; and colonizedsur patients were identified through surveillance protocols.